LL-37 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement. Common dosages range from 100-500 mcg (topical/local application) administered topical or local application as needed. Below are the most frequently asked questions.
Frequently Asked Questions About LL-37
What is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What is the recommended LL-37 dosage?
Common dosages range from 100-500 mcg (topical/local application), administered topical or local application as needed via topical wound application, local injection, intranasal. Cycles typically run acute use as needed.
What are the side effects of LL-37?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Is LL-37 legal?
Not FDA-approved as therapeutic. Research compound. Derivatives in late-stage clinical trials.
What is the half-life of LL-37?
The half-life of LL-37 is rapidly degraded by proteases; major clinical limitation, which determines the topical or local application as needed dosing schedule.
How do you reconstitute LL-37?
Add bacteriostatic water to the lyophilized LL-37 vial. Let the water run down the side — never spray on the powder. Swirl gently. Use our peptide calculator for exact amounts.
Can you stack LL-37 with other peptides?
Pairs with BPC-157 for wound healing — LL-37 handles antimicrobial defense while BPC-157 promotes tissue repair.
Where can you buy LL-37?
LL-37 is available as a research chemical from vetted suppliers with third-party COA testing.
How long does it take LL-37 to work?
Initial effects may be noticed within 1-2 weeks, with more significant results typically appearing by weeks 4-8 of a acute use as needed cycle.
What makes LL-37 unique?
The human body's own antibiotic peptide with multiple killing mechanisms that prevent bacterial resistance development — unlike conventional antibiotics, bacteria cannot easily evolve resistance to membrane disruption.
Complete Guide
LL-37 : Benefits, Dosage, Side Effects & Research
Related Reading
- LL-37 Dosage Guide
- LL-37 Benefits
- LL-37 Side Effects
- LL-37 Stacking Guide
- LL-37 Cycle Guide
- LL-37 Research
Calculate Your LL-37 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for LL-37.
Open Calculator →Research-Grade Sourcing
If you're going to research LL-37, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What is the recommended LL-37 dosage?
Common dosages: 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal. Cycle length: acute use as needed. Half-life: rapidly degraded by proteases; major clinical limitation. Use our peptide calculator for exact reconstitution math.
What are the side effects of LL-37?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Is LL-37 safe?
LL-37 has shown a preliminary safety profile in research. Not FDA-approved as therapeutic. Research compound. Derivatives in late-stage clinical trials. All research should follow appropriate safety protocols.